The Central government’s ambitious plan to set up bulk drug parks at Baddi in Himachal Pradesh, besides in Visakhapatnam, Ahmedabad and Tamil Nadu to boost bulk drug production in the country remains a non-starter even after nearly three years of the announcement

The decision was taken in this regard by the Centre to reduce dependence of Indian pharmaceutical companies on Chinese firms for active pharmaceutical ingredients (APIs). Around 75-80% of the APIs used in the formulations of National List of essential medicines are sourced from China. In 2017, India imported APIs worth $2.5 billion from China. Bulk drugs or APIs are the active raw materials used in a drug that give it the therapeutic effect
Many members are interested to provide every support to early set up of this park,” said Himachal Drug Manufacturers Association president Dr Rajesh Gupta

here is company details.

 

NOTE :You need to login first to access this feature.